ADAR1 Polyclonal Antibody | Bioss bs-2167R product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Bioss

product type :

antibody

product name :

ADAR1 Polyclonal Antibody

catalog :

bs-2167R

quantity :

100 ul

price :

279 USD

clonality :

polyclonal

host :

rabbit

conjugate :

nonconjugated

reactivity :

human

application :

western blot, immunocytochemistry, immunohistochemistry - paraffin section

product information

sku :

bs-2167R

name :

ADAR1 Polyclonal Antibody

category :

Primary Antibody

conjugation :

Unconjugated

host :

Rabbit

target protein :

ADAR1

modification :

Unmodified

clonality :

Polyclonal

isotype :

IgG

concentration :

1ug/ul

public immunogen range :

150-200/1226

subcellular locations :

Cytoplasm, Nucleus

source :

KLH conjugated synthetic peptide derived from human ADAR1

gene id link :

Entrez Gene: 103

swiss prot :

P55265

swiss prot link :

Swiss Prot: P55265

applications :

WB, IHC-P, IF(IHC-P)

applications with dilutions :

WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)

cross reactive species :

Human

size :

100 ul

price :

279 USD

background :

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence.

purification :

Purified by Protein A.

storage :

Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.

synonyms :

DSH; AGS6; G1P1; IFI4; P136; ADAR1; DRADA; DSRAD; IFI-4; K88DSRBP; Double-stranded RNA-specific adenosine deaminase; 136 kDa double-stranded RNA-binding protein; Interferon-inducible protein 4; ADAR

lead time :

3 to 5 business days.